Success and Momentum Involving Biomarkers in Lung Cancer Has Led to More Treatment Options for Patients
In an interview with CURE®, Dr. Jorge Gomez discussed how recent developments in the assessment of biomarkers within the small cell lung cancer and non-small cell lung cancer space have led to approvals of new and expanded therapies.
Tecentriq Approval in NSCLC 'Stops the Brakes' on PD-L1 Expression
An expert explains the importance of the fourth approval of the immunotherapy Tecentriq for certain patients with metastatic non-small cell lung cancer who have a high PD-L1 expression.